Change in total lesion glycolysis and clinical outcome after 90Y radioembolization in intrahepatic cholangiocarcinoma

Nuclear Medicine and Biology

Volumn 42, Issue 1, 2015, Pages 59-64

  Filippi, Luca ^a   Pelle, Giuseppe ^a   Cianni, Roberto ^a   Scopinaro, Francesco ^b   Bagni, Oreste ^a  

^a SANTA MARIA GORETTI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

90Y radioembolization; Intrahepatic cholangiocarcinoma; Total lesion glycolysis; 18F FDG PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MACROSALB TC 99M; RADIOACTIVE MICROSPHERE; YTTRIUM 90; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DISTRIBUTION; EMBOLIC PARTICLE; FEMALE; FOLLOW UP; GASTRITIS; GLYCOLYSIS; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIOEMBOLIZATION; RADIOISOTOPE THERAPY; TREATMENT RESPONSE; ADVERSE EFFECTS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; INTRAHEPATIC BILE DUCT; METABOLISM; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION RESPONSE; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84920384511     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.08.011     Document Type: Article

References (24)

1. Altaee M.Y., Johnson P.J., Farrant J.M., Williams R. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 1991, 68:2051-2055.
2. Yi B., Zhang B.H., Zhang Y.J., Jiang X.Q., Zhang B.H., Yu W.L., et al. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2004, 3:453-457.
3. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96:896-902.
4. Burger I., Hong K., Schulick R., Georgiades C., Thuluvath P., Choti M., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005, 16:353-361.
5. Aliberti C., Benea G., Tilli M., Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008, 31:883-888.
6. Cianni R., Urigo C., Notarianni E., Saltarelli A., D'Agostini A., Iozzino M., et al. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med 2010, 115:619-633.
7. Cianni R., Pelle G., Notarianni E., Saltarelli A., Rabuffi P., Bagni O., et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013, 23:182-189.
8. Padia S.A., Kwan S.W., Roudsari B., Monsky W.L., Coveler A., Harris W.P. Superselective Yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol 2014, 10.1016/j.jvir.2014.03.030.
9. Sato K.T., Lewandowski R.J., Mulcahy M.F., Atassi B., Ryu R.K., Gates V.L., et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 2008, 247:507-515.
10. Jakobs T.F., Hoffmann R.T., Fischer T., Stemmler H.J., Tatsch K., La Fougere C., et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008, 19:683-690.
11. Hoffmann R.T., Paprottka P.M., Schön A., Bamberg F., Haug A., Dürr E.M., et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012, 35:105-116.
12. Mouli S., Memon K., Baker T., Benson A.B., Mulcahy M.F., Gupta R., et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013, 24:1227-1234.
13. Ibrahim S.M., Mulcahy M.F., Lewandowski R.J., Sato K.T., Ryu R.K., Masterson E.J., et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008, 113:2119-2128.
14. Sabet A., Ahmadzadehfar H., Bruhman J., Sabet A., Meyer C., Wasmuth J.C., et al. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin 2014, 53:39-45.
15. Gulec S.A., Suthar R.R., Barot T.C., Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 2011, 38:1289-1295.
16. Kennedy A., Nag S. Reccomendations for radioembolization of hepatic malignancy using yttrium-90 microspheres brachytherapy: a consensus panel report from the radioembolization. Int J Radiat Oncol Biol Phys 2007, 68:13-23.
17. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S.
18. Bagni O., D'Arienzo M., Chiaramida P., Chiacchiararelli L., Cannas P., D'Agostini A., et al. 90Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy. Nucl Med Commun 2012, 33:198-204.
19. Martin L.K., Cucci A., Wei L., Rose J., Blazer M., Schmidt C., et al. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer 2012, 11:195-199.
20. Wong C.Y., Salem R., Raman S., Gates V.L., Dworkin H.J. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002, 29:815-820.
21. Filippi L., D'Arienzo M., Scopinaro F., Salvatori R., Bagni O. Usefulness of dual-time point imaging after carbonated water for the fluorodeoxyglucose positron emission imaging of peritoneal carcinomatosis in colon cancer. Cancer Biother Radiopharm 2013, 28:29-33.
22. Haug A.R., Heinemann V., Bruns C.J., Hoffmann R., Jakobs T., Bartenstein P., et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 2011, 38:1037-1045.
23. Fendler W.P., Philippe Tiega D.B., Ilhan H., Paprottka P.M., Heinemann V., Jakobs T.F., et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med 2013, 54:1202-1208.
24. 90Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 2012, 39:1391-1399.